BioSpace News Archive

Freenome, a privately held biotech company, today announced the initiation of Vallania, a clinical study for the refinement and further development of its multiomics platform to detect multiple cancers.

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 11:10 a.m. Eastern Time.

BioAge Labs, Inc. (link), a clinical-stage biotechnology company and global leader in using artificial intelligence (AI) and machine learning (ML) to develop drugs that target the molecular causes of aging, today announced that the Company will participate in a panel discussion at the Truist Securities Life Sciences AI Symposium.

Element Biosciences Inc. today announced partnerships with both Google DeepVariant and Sentieon for variant calling analysis.

Twist Bioscience Corporation today announced it has become a part of the Digital Preservation Coalition’s (DPC) Supporter Program, where members and solution providers can collaborate.

Rallybio Corporation today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “ Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced that physicians in the U.S. have successfully completed first cases with its new Lightbox 3 imaging console.

Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine® brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor.

Acasti Pharma Inc. today recognizes and celebrates Rare Disease Day (February 28), as established by the European Organisation for Rare Diseases.

Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the appointment of David E. Gauden, D.Phil. as its new Chief Executive Officer (CEO).